Skip to main content
. Author manuscript; available in PMC: 2015 Apr 28.
Published in final edited form as: Am J Transplant. 2013 Feb 22;13(4):954–960. doi: 10.1111/ajt.12147

Figure 2. Risk of (A) renal ACR, (B) renal AMR and (C) liver allograft rejection in patients with preformed class II DSA with MFI > 2000.

Figure 2

(D) Induction decreased the risk of rejection but did not change the overall survival impairment. Induction used was Daclizumab in 16 patients, Daclizumab plus Thymoglobulin in three patients, and OKT3 in two patients. All rejections are biopsy proven